SEC Form 4 · accession 0001104659-15-049016

CATABASIS PHARMACEUTICALS INC · CATB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

SV LIFE SCIENCES FUND V LP

10% Owner

SV Life Sciences Fund V Strategic Partners, L.P.

10% Owner

SV Life Sciences Fund V (GP), LP

10% Owner

SVLSF V, LLC

10% Owner

Period of report

Jun 30, 2015

Accepted (ET)

Jun 30, 2015 · 6:46 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001454789

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F4	Jun 30, 2015	C	1,651,223	—	A	1,651,223	I	See Footnotes
Common Stock^F1,F3,F4	Jun 30, 2015	C	34,893	—	A	34,893	I	See Footnotes
Common Stock^F1,F2,F4	Jun 30, 2015	C	764,309	—	A	2,415,532	I	See Footnotes
Common Stock^F1,F3,F4	Jun 30, 2015	C	16,152	—	A	51,045	I	See Footnotes
Common Stock^F2,F4	Jun 30, 2015	P	382,996	$12.00	A	2,798,528	I	See Footnotes
Common Stock^F3,F4	Jun 30, 2015	P	8,094	$12.00	A	59,139	I	See Footnotes

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F2,F4,F1	—	Jun 30, 2015	C	21,218,253	D	—	—	Common Stock	1,651,223	I
Series A Preferred Stock^F3,F4,F1	—	Jun 30, 2015	C	448,414	D	—	—	Common Stock	34,893	I
Series B Preferred Stock^F2,F4,F1	—	Jun 30, 2015	C	9,821,385	D	—	—	Common Stock	764,309	I
Series B Preferred Stock^F3,F4,F1	—	Jun 30, 2015	C	207,558	D	—	—	Common Stock	16,152	I

Explanation of responses

F1The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The members of the investment committee of SVLSF V, LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP and SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaim beneficial ownership of the shares owned directly by SVLS V LP except to the extent of any pecuniary interest therein.
F3These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The members of the investment committee of SVLSF V, LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP and SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaim beneficial ownership of the shares owned directly by SVLS V SPP except to the extent of any pecuniary interest therein.
F4SVLS V LP and SVLS V SPP (each a "Fund," or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein.